Why the study?
Do cardiovascular drugs given before or during the acute phase reduce 28-day mortality in patients with acute myocardial infarction?
Do cardiovascular drugs given before or during the acute phase reduce 28-day mortality in patients with acute myocardial infarction?
The administration of antiplatelet drugs and beta-blockers during the acute phase of myocardial infarction substantially reduces 28-day mortality.
Answers are grounded in this paper and cite their sources.
Acute-phase antiplatelet and beta-blocker use was associated with lower AMI mortality; hypothesis-generating and requires RCT confirmation before practice change.
PURPOSE: To quantify the impact of cardiovascular drugs used before the acute myocardial infarction (AMI) and given during the acute phase on reduction in the risk of death during the first 28 days after an AMI. METHODS: The Northern Sweden MONICA database on incident AMI was analysed with regard to drug use before and during the acute phase of the myocardial infarction and the risk of death within the first 28 days. All patients admitted to a hospital in this area with a suspected diagnosis of AMI were included in this database. RESULTS: No drugs used before and up to the acute myocardial infarction provided protection against death in the AMI in this analysis. Among drugs given during the acute phase, antiplatelet drugs and betablocking drugs reduced the risk of death in the AMI and to a lesser degree, anticoagulants and nitrates provided protection. CONCLUSIONS: The administration of antiplatelet drugs and betablockers in the acute phase of an AMI substantially reduces the risk of death during the first 28 days after an AMI for the individual.
No takes yet. Share an insight, caveat, or question.
Messner et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: